Excreted Unchanged %
60-90
Half-Life (Normalesrd) Hours
250 days/No data
Plasma Protein Binding %
95
Volume Of Distribution L/Kg
5-9
Dose For Normal Renal Function
25-50 mg
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
50% [B]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
Avoid [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
Avoid [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Avoid
References
Bergstrom RF, Kay DR, Harkcom TM, Wagner JG. Penicillamine kinetics in normal subjects. Clin Pharmacol Ther. 1981; 30: 404-13. [PMID: 7273605] / Blocka KL, Paulus HE, Furst DE. Clinical pharmacokinetics of oral and injectable gold compounds. Clin Pharmacokinet. 1986; 11: 133-43. [PMID: 3082559] / Lange K. Nephropathy induced by D-penicillamine. Contrib Nephrol. 1978; 10: 63-74. [PMID: 97051] / Lorber A. Monitoring gold plasma levels in rheumatoid arthritis. Clin Pharmacokinet. 1977; 2: 127-46. [PMID: 324688]
Toxicity Notes
Proteinuria, nephrotic syndrome, membranous nephritis.